with potential applications in cardio-pulmonary and neuro-inflammatory indications.
JN Nova is a clinical-stage biopharmaceutical company, focused on efficiently developing innovative treatments that address significant unmet medical needs.
JN Nova’s lead product candidate, KG2019 is a novel anti-COVID-19 molecule. The company is collaborating with Canadian Government labs and Canadian academic centers to accelerate its COVID-19 therapeutic development.
JN Nova Pharma Inc. responded with unprecedented speed and assembled a world-class Canadian team to rapidly develop a therapeutic to SARS-CoV-2. In a few days, we designed a novel therapeutic to COVID-19 and signed a co-development agreement with NRC-HHT. We're deeply impressed with the speed at which Canadian partners came together to address this global challenge. Together, our teams are committed to delivering a Canadian-made countermeasure to stop this Pandemic.
About
Nearly all serious cases of COVID-19 feature rapidly progressive pneumonia, diffuse alveolar damage, severe acute respiratory distress syndrome, respiratory failure and ultimately fibrosis. The most common cause of death in COVID-19 patients is ARDS. According to evolving data from the current global pandemic, COVID-19-associated ARDS patients have similar compromised respiratory system mechanics to patients with ARDS from other causes, for which Renin-angiotensin system (RAS) has been strongly implicated in the pathogenesis. This is ascribed to a generalized over-production of Angiotensin II.
The COVID19 virus, by targeting of ACE2, eliminates the countervailing Alternative RAS, which is mediated by angiotensin-(1–7), whose loss severely exacerbates ARDS. Ang II is responsible for many acute symptoms of COVID 19 -induced ARDS:
Our therapeutic approach is being developed to provide a fast response to these symptoms of Acute Respiratory Distress Syndrome in COVID19 patients, preventing decline and reducing subsequent pathology.
About
As in other viral pneumonias, COVID19 infection also causes stimulation of inflammatory cytokines, causing injury to the respiratory tract and associated vascular endothelial damage, which is often seen to a far greater extent in COVID patients than in viral pneumonia. Protection from an exaggerated innate immune response and impact on T-cell responses as a function of disease severity is to be addressed by our proprietary immunomodulatory approach.
We are developing novel therapeutics for COVID-19, with potential applications in cardio-pulmonary and neuro-inflammatory indications.
